Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation
- PMID: 16181711
- DOI: 10.1016/j.vaccine.2005.08.017
Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation
Abstract
A plasmid DNA vaccine containing a fusion gene consisting of an HIV-1 subtype C gag and a modified subtype C pol was compared to a mixture of gag plus pol or gag plus HIV env plasmids. Plasmid DNA was delivered by intramuscular injection followed by electroporation in vivo. Two vaccinations were sufficient to induce high levels of Gag- and Pol-specific CD4 and CD8 T cells in peripheral blood. The gag-pol fusion plasmid was as immunogenic as the plasmid mixtures. Thus, DNA vaccination by intramuscular electroporation was an effective means for inducing high levels of Gag- and Pol-specific T cells, and a single gag-pol fusion DNA vaccine was sufficient for eliciting immune responses against both antigens.
Similar articles
-
Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.Vaccine. 2006 Apr 5;24(15):2755-63. doi: 10.1016/j.vaccine.2006.01.013. Epub 2006 Jan 19. Vaccine. 2006. PMID: 16460840
-
Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.Eur J Immunol. 2008 May;38(5):1310-20. doi: 10.1002/eji.200738069. Eur J Immunol. 2008. PMID: 18412164
-
Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.J Virol. 2003 Jun;77(11):6197-207. doi: 10.1128/jvi.77.11.6197-6207.2003. J Virol. 2003. PMID: 12743276 Free PMC article.
-
DNA vaccines against human immunodeficiency virus type 1.Immunol Rev. 2004 Jun;199:144-55. doi: 10.1111/j.0105-2896.2004.00151.x. Immunol Rev. 2004. PMID: 15233732 Review.
-
New hope for an AIDS vaccine.Nat Rev Immunol. 2002 Apr;2(4):239-50. doi: 10.1038/nri776. Nat Rev Immunol. 2002. PMID: 12001995 Review.
Cited by
-
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.Mol Ther. 2010 Aug;18(8):1568-76. doi: 10.1038/mt.2010.112. Epub 2010 Jun 15. Mol Ther. 2010. PMID: 20551910 Free PMC article.
-
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".J Virol. 2008 Apr;82(7):3166-80. doi: 10.1128/JVI.01634-07. Epub 2007 Nov 7. J Virol. 2008. PMID: 17989174 Free PMC article. Review. No abstract available.
-
DNA vaccines: ready for prime time?Nat Rev Genet. 2008 Oct;9(10):776-88. doi: 10.1038/nrg2432. Nat Rev Genet. 2008. PMID: 18781156 Free PMC article. Review.
-
Polymeric Materials for Gene Delivery and DNA Vaccination.Adv Mater. 2009 Feb 23;21(8):847-867. doi: 10.1002/adma.200801478. Epub 2008 Dec 4. Adv Mater. 2009. PMID: 28413262 Free PMC article.
-
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.Vaccine. 2010 Feb 23;28(8):1962-74. doi: 10.1016/j.vaccine.2009.10.099. Vaccine. 2010. PMID: 20188252 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials